Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue	$ 29,784	$ 24,519
Cost of goods sold	7,256	5,403
Gross profit	22,528	19,116
Operating expenses:
Research and development	3,519	3,761
Clinical and regulatory affairs	2,364	1,402
Marketing and sales	15,249	13,547
General and administrative	5,885	4,080
Total operating expenses	27,017	22,790
Loss from operations	(4,489)	(3,674)
Other income (expense):
Interest income	10	3
Interest Expense	0	(7)
Other income (expense), net	684	(1)
Change in fair value of contingent consideration related to acquisition	(5,200)	(12,450)
Total other expense	(4,506)	(12,455)
Net loss before income tax expense	(8,995)	(16,129)
Income tax expense	(339)	(574)
Net loss	(9,334)	(16,703)
Other comprehensive income (foreign currency translation)	328	5
Comprehensive loss	$ (9,006)	$ (16,698)
Basic and diluted net loss per share (usd per share)	$ (0.15)	$ (0.29)
Shares used in computing basic and diluted net loss per share (shares)	62,189	57,620